T. Holzkämper

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis

P. López-Romero, M. Matucci-Cerinic, G. Burmester, 2022, Rheumatology and Therapy.

Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting

G. Fabbrocini, T. Torres, L. Puig, 2022, Advances in Therapy.

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

P. Emery, Yoshiya Tanaka, P. Durez, 2021, Arthritis Research & Therapy.

P220 An updated safety profile of baricitinib for the treatment of RA up to 7 years

M. Genovese, J. Smolen, P. Durez, 2020 .

Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN

P. López-Romero, E. Feist, I. de la Torre, 2020, Arthritis Research & Therapy.

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies

B. Jia, M. Weinblatt, Yushi Liu, 2023, Rheumatology and Therapy.

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis

B. Kirkham, L. Puig, J. Merola, 2023, Rheumatology and Therapy.